These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35261761)

  • 1. Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes.
    Ariceta G; Fakhouri F; Sartz L; Miller B; Nikolaou V; Cohen D; Siedlecki AM; Ardissino G
    Clin Kidney J; 2021 Sep; 14(9):2075-2084. PubMed ID: 35261761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.
    Macia M; de Alvaro Moreno F; Dutt T; Fehrman I; Hadaya K; Gasteyger C; Heyne N
    Clin Kidney J; 2017 Jun; 10(3):310-319. PubMed ID: 28621343
    [No Abstract]   [Full Text] [Related]  

  • 3. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
    Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study.
    Menne J; Delmas Y; Fakhouri F; Kincaid JF; Licht C; Minetti EE; Mix C; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
    Clin Kidney J; 2019 Apr; 12(2):196-205. PubMed ID: 30976396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
    Menne J; Delmas Y; Fakhouri F; Licht C; Lommelé Å; Minetti EE; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
    BMC Nephrol; 2019 Apr; 20(1):125. PubMed ID: 30971227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan.
    Ito S; Hataya H; Ashida A; Hamada R; Ishikawa T; Ishikawa Y; Shimono A; Konomoto T; Miyazawa T; Ogura M; Tanaka K; Kagami S
    Nephrol Dial Transplant; 2023 Feb; 38(2):414-424. PubMed ID: 35438790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation.
    Duineveld C; Bouwmeester RN; Wijnsma KL; Bemelman FJ; van der Heijden JW; Berger SP; van den Heuvel LPWJ; van de Kar NCAJ; Wetzels JFM;
    Kidney Int Rep; 2023 Apr; 8(4):715-726. PubMed ID: 37069997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.
    Legendre CM; Campistol JM; Feldkamp T; Remuzzi G; Kincaid JF; Lommelé Å; Wang J; Weekers LE; Sheerin NS
    Transpl Int; 2017 Dec; 30(12):1275-1283. PubMed ID: 28801959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome.
    AlZabali S; AlBatati S; Rahim K; Faqeehi H; Osman A; Bamhraz A; Saleh MA; Kari JA; Aloufi M; Eid L; Nasser H; Imam A; AlHammadi E; Alkandari O; Al Riyami M; Sethi S; Licht C; Alhasan KA; AlAnazi A
    Children (Basel); 2022 Nov; 9(11):. PubMed ID: 36421183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission of aHUS neurological damage with eculizumab.
    Ávila A; Vizcaíno B; Molina P; Gavela E; Perez-Ebri M; Pallardó L
    Clin Kidney J; 2015 Apr; 8(2):232-6. PubMed ID: 25815183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report.
    Nunius C; Büttner-Herold M; Bertz S; Schiffer M; Buchholz B
    BMC Nephrol; 2020 Mar; 21(1):104. PubMed ID: 32204691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis.
    Gonzalez Suarez ML; Thongprayoon C; Mao MA; Leeaphorn N; Bathini T; Cheungpasitporn W
    J Clin Med; 2019 Jun; 8(7):. PubMed ID: 31252541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
    Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort.
    Nga HS; Palma LMP; Ernandes Neto M; Fernandes-Charpiot IMM; Garcia VD; Kist R; Miranda SMC; Macedo de Souza PA; Pereira GM; de Andrade LGM
    PLoS One; 2021; 16(11):e0258319. PubMed ID: 34748552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
    Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM; Arias M; Ariceta G; Blasco M; Espinosa L; Espinosa M; Grinyó JM; Macía M; Mendizábal S; Praga M; Román E; Torra R; Valdés F; Vilalta R; Rodríguez de Córdoba S
    Nefrologia; 2015; 35(5):421-47. PubMed ID: 26456110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of a scoring system in Japanese patients diagnosed with atypical hemolytic uremic syndrome to assess the relationship between the score and clinical responses to eculizumab.
    Wada H; Teranishi H; Shimono A; Kato N; Maruyama S; Matsumoto M
    Thromb J; 2023 Apr; 21(1):43. PubMed ID: 37072821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.